GB:AZN Stock Latest News

Investor backlash killed AstraZeneca, Bristol Myers tie-up, FT reports

PremiumThe Fly

5d ago

Trump Trade: President signs EO to split up of childhood vaccines

PremiumThe Fly

5d ago

Trump signs EO to split up of childhood vaccines, Bloomberg reports

PremiumThe Fly

6d ago

Trump Trade: U.S. issues 15% duty on products made from polysilicon

PremiumThe Fly

9d ago

PremiumThe FlyTrump admin plans to issue executive order on vaccines, autism, Bloomberg says

9d ago

AstraZeneca: Buy Rating Reiterated on Attractive Valuation, Robust Pipeline, and Unchanged $16,500 Price Target

Ratings

AstraZeneca: Buy Rating Reiterated on Attractive Valuation, Robust Pipeline, and Unchanged $16,500 Price Target

9d ago

Unusually active option classes on open August 5th

The Fly

Unusually active option classes on open August 5th

11d ago

Best Buy downgraded, Bristol Myers upgraded: Wall Street’s top analyst calls

DIS

PremiumThe Fly

11d ago

Bristol Myers, AstraZeneca not engaged in merger talks, Reuters reports

BBY

PremiumThe Fly

11d ago

AstraZeneca deal talks with Bristol Myers remain active, Semafor says

PremiumThe Fly

12d ago

AstraZeneca’s Eluminate-3 Trial Targets New Diabetes Growth Path

PremiumCompany Announcements

12d ago

PremiumCompany AnnouncementsAstraZeneca Advances Early Combo Study With AZD0780 and AZD4954, Signaling Steady Pipeline Progress

12d ago

TD Cowen sees no strategic logic in an AstraZeneca-Bristol Myers merger

The Fly

TD Cowen sees no strategic logic in an AstraZeneca-Bristol Myers merger

13d ago

AstraZeneca’s Elecoglipron Trial: Early Signals for a Future Oral Metabolic Franchise

Company Announcements

AstraZeneca’s Elecoglipron Trial: Early Signals for a Future Oral Metabolic Franchise

13d ago

Midday Fly By: Amazon passes $3T market cap, Astra in tie-up talks with Bristol

PremiumThe Fly

13d ago

PremiumCompany Announcements

AstraZeneca Adds Employee Scheme Shares to London Listing

13d ago

AstraZeneca Updates Market on Total Voting Rights

PremiumCompany Announcements

13d ago

Morning Movers: Supernus and Indivior jump following merger pact

PremiumThe Fly

13d ago

PremiumThe FlyVideo: Bristol Myers jumps, AstraZeneca sinks on report of tie-up talks

13d ago

AstraZeneca: Buy Rating Reaffirmed as Robust Pipeline and Strategic Optionality Drive Price Target Raise to $178

Ratings

AstraZeneca: Buy Rating Reaffirmed as Robust Pipeline and Strategic Optionality Drive Price Target Raise to $178

13d ago

Sachin Jain Reiterates Buy on AstraZeneca with Unchanged 16,500 GBp Price Target Amid Valuation Opportunity and Robust Late-Stage Pipeline

Ratings

Sachin Jain Reiterates Buy on AstraZeneca with Unchanged 16,500 GBp Price Target Amid Valuation Opportunity and Robust Late-Stage Pipeline

13d ago